About Rare Mutations and Fusions in Lung Cancer
Currently, there are 12 DNA-based alterations, or biomarkers, for which we have targeted therapies in NSCLC. Rare mutations and fusions include BRAF V600E, MET, NTRK, RET and ROS1.
New & Upcoming Events for Rare Mutations
Latest Updates in Rare Mutations
-
Podcast: Managing the Emotional Rollercoaster of Lung Cancer
Living with lung cancer can take more than just a physical toll—it comes with a myriad of feelings, like anxiety, fear, and grief. In this episode, non-small cell lung cancer... -
Real Progress and Real Gaps: Highlights of the 2026 AACR Disparities Report
I have spent my career focused on the intersection between cancer research and public health. Since joining LUNGevity over a decade ago, it has been nothing short of a privilege to... -
New Treatment Approved for ROS1-positive NSCLC
On July 22, 2026, the US Food and Drug Administration (FDA) announced the approval of zidesamtinib (Jideytro™) to treat patients with locally-advanced or metastatic ROS1-positive...
Sponsors
